A quantitative comparison of essential cardiovascular medicines from countries in the Southern African Development Community to the WHO model essential medicines list

Informa UK Limited
Ian Naicker1, Fátima Suleman2, Velisha Ann Perumal-Pillay1
1Discipline of Pharmaceutical Sciences, University of KwaZulu-Natal, Durban, South Africa
2College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa

Tóm tắt

Abstract Background Globally, cardiovascular disease (CVD) is a leading cause of death and disproportionately affects low- and middle-income countries (LMICs). The WHO Model List of Essential Medicines (WHO EML) is a tool for improving accessibility and availability of medicines. This study compared the 2021 WHO EML CVDs basket of medicines with latest available national essential medicines list (NEMLs) for South Africa and 15 Southern African Development Community (SADC) countries to assess consistency in CVDs medicine listing. Methods This descriptive, desktop review study compared SADC NEMLs. A comparator list was extracted by combining cardiovascular medicines listed in the 2021 WHO EML for adults and children. SADC country NEMLs were obtained from the WHO Essential Medicines and Health Products Information Portal. Consistency of NEMLs was calculated as a percentage coverage of CVD medicines listed in the 2021 WHO EML. SA hospital and primary health care (PHC) level NEMLs were included as separate formularies. Results The SA hospital level NEML scored 70% consistency with the 2021 WHO EML. Tanzania (84%), Namibia (81%) and Angola (79%) scored the highest consistency. The mean consistency for SADC NEMLs was 66%. The lowest scoring country was Eswatini at 26%. The SA PHC NEML scored 35%. The least listed medicines were beta-blockers, angiotensin receptor blockers (ARBs), clopidogrel (43%) and paediatric formulations (furosemide (21%); digoxin (43%)). Individual antihypertensive medicines were most commonly listed. Botswana and Lesotho were the only countries to list a single pill combination (SPC) for the treatment of hypertension. Conclusions This comparison indicates that South Africa and most SADC countries are aligned with 2021 WHO EML recommendations. The inclusion of age-appropriate formulations for children as well as ARBs and SPC for the treatment of hypertension may improve patient adherence and cardiovascular outcomes in these countries. More frequent updates to NEMLs should improve consistency. NEMLs were not available for two countries, and these therefore did not form part of this study. Country health expenditure in ranking the consistency of NEMLs was not accounted for. LMICs adopting the essential medicine list strategy should consider imposing minimum consistency thresholds to the WHO EML to improve accessibility and availability of CVD medicines. Trial registration: Not applicable.

Từ khóa


Tài liệu tham khảo

Fact Sheet: Cardiovascular Diseases: World Health Organization 2017. https://www.who.int/en/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds).

Keates AK, Mocumbi AO, Ntsekhe M, Sliwa K, Stewart S. Cardiovascular disease in Africa: epidemiological profile and challenges. Nat Rev Cardiol. 2017;14(5):273–93.

Amegah KA. Tackling the growing burden of cardiovascular diseases in Sub-Saharan Africa. Circulation. 2018;138(22):2449–51.

Chikafu H, Chimbari MJ. Cardiovascular disease healthcare utilization in sub-Saharan Africa: a scoping review. Int J Environ Res Public Health. 2019;16(3):419.

Mayosi BM, Flisher AJ, Lalloo UG, Sitas F, Tollman SM, Bradshaw D. The burden of non-communicable diseases in South Africa. Lancet. 2009;374:934–47.

Husain MJ, Datta BK, Kostova D, Joseph KT, Asma S, Richter P, et al. Access to cardiovascular disease and hypertension medicines in developing countries: an analysis of essential medicine lists, price, availability, and affordability. J Am Heart Assoc. 2020;9(9): e015302.

Raju PKS. WHO/HAI methodology for measuring medicine prices, availability and affordability, and price components. In: Vogler S, editor. Medicine price surveys, analyses and comparisons. Cambridge: Academic Press; 2019. p. 209–28.

WHO. Access to essential medicines. 2020. In: Monitoring the building blocks of health systems. Geneva: World Health Organization. https//:www.who.int/medicines/services/essmedicines_def/en/. Accessed 24 Sept 2020.

Kishore SP, Blank E, Heller DJ, Patel A. Modernizing the World Health Organisations List of Essential Medicines for Preventing and controlling cardiovascular disease. JACC. 2018;71(5):564–74.

Perumal-Pillay VA, Suleman F. Selection of essential medicines for South Africa—an analysis of in-depth interviews with national essential medicines list committee members. BMC Health Serv Res. 2017;17(1):17.

Persaud N, Jiang M, Shaikh R, Bali A, Oronsaye E, Woods H, et al. Comparison of essential medicines lists in 137 countries. Bull World Health Organ. 2019;97(6):394–404c.

Steiner L, Fraser S, Maraj D, Persaud N. Associations between essential medicines and health outcomes for cardiovascular disease. BMC Cardiovasc Disord. 2021;21(1):151.

Bazargani YT, Ugurlu M, de Boer A, Leufkens HGM, Mantel-Teeuwisse AK. Selection of essential medicines for the prevention and treatment of cardiovascular diseases in low and middle income countries. BMC Cardiovasc Disord. 2018;18(1):126.

Mehrtash H, Laing R, Wirtz VJ. Comparative analysis of essential medicines for cardiovascular diseases in countries of the WHO Eastern Mediterranean Region. East Mediterr Health J. 2018;24(5):427–34.

Dzudie A, Njume E, Abanda M, Aminde L, Hamadou B, Dzekem B, et al. Availability, cost and affordability of essential cardiovascular disease medicines in the south west region of Cameroon: preliminary findings from the Cameroon science for disease study. PLoS ONE. 2020;15(3): e0229307.

Organization WH. World Health Organization Model List of Essential Medicines—22nd List. Geneva: World Health Organisation; 2021 28 May 2022. Report No.: WHO/MHP/HPS/EML/2021.02.

Jarvis JD, Woods H, Bali A, Oronsaye E, Persaud N. Selection of WHO-recommended essential medicines for non-communicable diseases on National Essential Medicines Lists. PLoS ONE. 2019;14(8): e0220781.

Twagirumukiza M, Annemans L, Kips JG, Bienvenu E, Van Bortel LM. Prices of antihypertensive medicines in sub-Saharan Africa and alignment to WHO’s model list of essential medicines. Trop Med Int Health. 2010;15(3):350–61.

Kassim SA, Alolga RN, Assanhou AG, Kassim SM, Hongchao L, Aixia M. Medicine pricing: Impact on accessibility and affordability of medicines vis a vis the product origin as pharmaco-economic drivers in Comoros. J Public Health Epidemiol. 2015;7(9):274–93.

Kapwata T, Manda S. Geographic assessment of access to health care in patients with cardiovascular disease in South Africa. BMC Health Serv Res. 2018;18(1):1–10.

Lim SS, Gaziano TA, Gakidou E, Reddy KS, Farzadfar F, Lozano R, et al. Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs. Lancet. 2007;370(9604):2054–62.

Organization WH. WHO model list of essential medicines: 17th list, March 2011. 2011.

Ataklte F, Erqou S, Kaptoge S, Taye B, Echouffo-Tcheugui JB, Kengne AP. Burden of undiagnosed hypertension in sub-Saharan Africa: a systematic review and meta-analysis. Hypertension. 2015;65(2):291–8.

Schutte A. Urgency for South Africa to prioritise cardiovascular disease management. Lancet. 2018;32:e177–8.

Basu S, Wagner RG, Sewpaul R, Reddy P, Davies J. Implications of scaling up cardiovascular disease treatment in South Africa: a microsimulation and cost-effectiveness analysis. Lancet Glob Health. 2019;7(2):e270–80.

Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension global hypertension practice guidelines. Hypertension. 2020;75(6):1334–57.

Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018;39(33):3021–104.

Ajayi AL, Adigun A. Angioedema and cough in Nigerian patients receiving ACE inhibitors. Br J Clin Pharmacol. 2000;50(1):81.

Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, et al. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND®) Investigators: Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372(9644):1174–83.

Investigators O. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547–59.

Lehohla P. Use of health facilities and levels of selected health conditions in South Africa: findings from the General Household Survey, 2011: Statistics South Africa Pretoria; 2013.

AFRO W. Cardiovascular diseases in the African Region: Current Situation and Perspectives. Report of the Regional Director Fifty-fifth session Maputo, Mozambique. 2005:22–6.

Zühlke L, Mirabel M, Marijon E. Congenital heart disease and rheumatic heart disease in Africa: recent advances and current priorities. Heart. 2013;99(21):1554–61.

Thông tin
Thông tin xuất bản

Informa UK Limited

Thông tin tác giả